The good news keeps coming on the vaccine front, says Lex in the Financial Times – this time with positive results from AstraZeneca. The overall tally was “underwhelming”: the treatment’s average efficacy of 70% was “significantly less” than the figure achieved by the BioNTech/Pfizer and Moderna vaccines. But the best results, of 90% efficacy, were achieved for participants who only received half of the first of two doses. This suggests that “more people can get a shot with the same amount of vaccine”. AstraZeneca has already agreed deals with drugmakers in Russia, Brazil and India to produce up to three billion doses.
Despite this apparent success, the market has punished AstraZeneca, with the drug giant’s shares falling by 3.8% when the news was announced, says Nils Pratley in The Guardian. Part of this is due to the need to explain the “wide gap” between the 62% efficiency in the main study and 90% for those who received the half-dose, full dose regime. AstraZeneca’s pledge “to distribute the vaccine at cost during the course of pandemic” also means that it “won’t make profits from the initial orders”. Still, it’s impossible to deny that a 90% efficiency rate in one study is “excellent”.
Near-perfect protection
The near-perfect level of protection is particularly impressive given the way the trial was conducted, says The Economist. While the numbers of people involved were smaller than in rival studies, AstraZeneca repeatedly tested all those involved in the trial to pick up asymptomatic infections. As a result, the efficiency of AstraZeneca’s jab is not necessarily worse than that of Pfizer and Moderna, who relied on people self-reporting symptoms, followed by a confirmatory test. This is important because those who are asymptomatic can still pass on the virus to others, so AstraZeneca’s jab may ultimately reduce the transmission of the virus. The interim results “will certainly please the UK government”, says Ross Clark in The Spectator. Not only is it a “homegrown” vaccine, developed from research carried out by the University of Oxford, and part-funded by the state, but the UK has also ordered 100 million shots. What’s more, the facts that the vaccine itself “is less than a fifth of the price of the Pfizer vaccine” and can be “kept at ordinary fridge temperatures” will greatly facilitate a roll-out, as well as making it the “obvious choice” for developing countries.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
While Britain and America have ordered enough doses for their entire populations, most young and able-bodied people in other countries “may have to wait until 2022 to be vaccinated”, even with multiple vaccines, says Aimee Donnellan on Breakingviews. That means that many unvaccinated people could “keep avoiding public transport and mass gatherings”, which will “put a cap on any recovery in corporate profitability”.
-
Pension tax-free lump sum warning as early withdrawal could cost savers £63,000Savers could also be hit with income tax on money added to cash savings accounts
-
Reeves told scrapping pension salary sacrifice would cost average earner £377 a yearMPs – including chancellor Rachel Reeves – have received a letter warning of the dangers in reducing or removing salary sacrifice schemes for pension contributions, a plan under consideration by HMRC.
-
The Stella Show is still on the road – can Stella Li keep it that way?Stella Li is the globe-trotting ambassador for Chinese electric-car company BYD, which has grown into a world leader. Can she keep the motor running?
-
Global investors have overlooked these solid stocks going for growthOpinion Nisha Thakrar, investment specialist at Nedgroup Investments, selects three undervalued stocks with long-term growth potential
-
LVMH is set to prosper as the wealthy start shopping againAfter two years of uncertainty, the outlook for LVMH is starting to improve. Is now a good time to add the luxury-goods purveyor to your portfolio?
-
Japan is still rising to new highs – here's how to investOpinion Political ructions in Japan are no obstacle to gains, and the return of inflation may even benefit stocks, says Max King. What is Japan doing right?
-
Investors need to get ready for an age of uncertainty and upheavalTectonic geopolitical and economic shifts are underway. Investors need to consider a range of tools when positioning portfolios to accommodate these changes
-
Investing in UK universities: how to spin research into profitsUK universities are a vital economic asset, but they are also Britain's 'equivalent of Gulf oil.' There are opportunities here for investors
-
AI is a bet we’re forced to makeIt’s impossible to say yet if AI will revolutionise the world, but failure would clearly be very costly, says Cris Sholto Heaton
-
The MoneyWeek Wealth Summit 2025: how to invest for a volatile eraMoneyWeek's 25th birthday conference’s agenda offers investors a wide array of compelling themes
